Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting

WALTHAM, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi), today announced the presentation of three abstracts that highlights data from its myelofibrosis treatment option at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31 – June 4, 2024.

Sobi’s commitment to delivering innovative treatments for people living with hematological diseases is seen in global studies spanning multiple rare disorders, including myelofibrosis.

A retrospective analysis will be presented that demonstrates the efficacy of pacritinib in spleen volume reduction, symptom benefit and red blood cell transfusion response, compared with best available therapy, in patients with myelofibrosis who have both thrombocytopenia and anemia.

An additional retrospective analysis will be presented that shows the substantial symptom benefit pacritinib provides compared with best available therapy or low-dose ruxolitinib, specifically in patients who required red blood cell transfusion at the time of pacritinib initiation. The number of patients experiencing treatment emergent Grade 3 anaemia was similar between pacritinib and BAT groups.

New real-world data will be presented that demonstrates treatment with pacritinib provides stability or improvement in thrombocytopenia and/or anemia in patients with myelofibrosis, regardless of baseline counts, and has favorable overall survival similar to other JAK inhibitor historical controls.

Key Sobi data to be presented at ASCO 2024

Myelofibrosis
Vonjo (pacritinib)	Impact of pacritinib on symptoms in patients with thrombocytopenia and myelofibrosis who require red blood cell transfusion	Poster presentation #6577 Monday, 3 June, 2024; 9:00 - 12:00 CDT
	Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia	Poster presentation #6578 Monday, 3 June, 2024; 9:00 - 12:00 CDT
	Real-world treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib in the United States	Poster presentation #6579 Monday, 3 June, 2024; 9:00 - 12:00 CDT

All abstracts can be accessed via the official ASCO website.

Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media, click here.